Evidence map›Paper›PMID 34291554›Full record

ArticleCNS neuroscience & therapeutics2021

Recognition of seizure semiology and semiquantitative FDG-PET analysis of anti-LGI1 encephalitis.

Tao-Ran Li, Yu-Di Zhang, Qun Wang, Xiao-Qiu Shao, Rui-Juan Lv

Abstract read
In one paragraph

Article in CNS neuroscience & therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Frontiers in neurology · 2026
    Article
  2. MedComm · 2025
    Article
  3. Comparison ofEuropean journal of nuclear medicine and molecular imaging · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tao-Ran LiDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases, Beijing, China.ORCID 0000-0002-0451-2850
Yu-Di ZhangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases, Beijing, China.
Qun WangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases, Beijing, China.
Xiao-Qiu ShaoDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases, Beijing, China.
Rui-Juan LvDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases, Beijing, China.ORCID 0000-0002-9927-847X

Funding

the Application Research of Capital Clinical Characteristics Z181100001718082The Beijing Dongcheng District Outstanding Talent Funding Project 2019DCT-M-18the National Science Foundation of Beijing Tiantan Hospital YZR-2021-06
6 · The paper itself

Abstract

aimsAnti-leucine-rich glioma-inactivated 1 (LGI1) autoimmune encephalitis (AE) is characterized by complex manifestations of seizures. Here, we report a new seizure semiology, attempt to classify the disease by semiology type, and explore the metabolic pattern of each group.

methodsAnti-LGI1 AE patients were retrospectively screened between May 2014 and September 2019 in our tertiary epilepsy center. All enrolled patients had seizures during long-range video electroencephalogram (EEG) recordings, and all patients (except one) underwent [

resultsThirty-three patients were enrolled. According to the patients' seizure semiology, we divided the patients into four groups: focal impaired awareness seizures (FIAS, n = 17), faciobrachial dystonic seizures (FBDS)-only (n = 6), FBDS-plus (n = 8), and focal aware motor seizures (FAMS) (n = 2). No significant differences were found in the clinical manifestations or accessory tests except for the onset age (FIAS < FBDS-plus) and seizure semiology. This was the first study to extensively describe the clinical manifestations and EEG of FAMS in anti-LGI1 AE patients. In addition, we found that the patients with different semiologies all showed a wide range of abnormal metabolism, which is not limited to the temporal regions and basal ganglia, and extends far beyond our previous interpretation of FDG-PET data.

conclusionOur results showed that FAMS can serve as a rare indicative seizure semiology of anti-LGI1 AE and that individuals with this disease exhibited widespread functional network alterations.

Indexed as

AdultAgedAge of OnsetAutoantibodiesAutoimmune DiseasesElectroencephalographyEncephalitisFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedPositron-Emission TomographyRadiopharmaceuticalsRetrospective StudiesSeizuresanti-leucine-rich glioma-inactivated 1 autoantibodyAutoantibodiesFluorodeoxyglucose F18Radiopharmaceuticalsautoimmune encephalitisFDG-PETLGI1seizure semiology

Identifiers

PMID34291554
PMCPMC8446218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.